AstraZeneca (LON:AZN) Stock Rating Reaffirmed by UBS Group
AstraZeneca (LON:AZN)‘s stock had its “sell” rating restated by equities research analysts at UBS Group in a report issued on Wednesday, ThisIsMoney.Co.Uk reports. They presently have a GBX 5,700 ($74.48) target price on the biopharmaceutical company’s stock, up from their prior target price of GBX 5,400 ($70.56). UBS Group’s price target would suggest a potential downside of 21.16% from the stock’s current price.
A number of other equities analysts have also issued reports on the stock. Deutsche Bank reiterated a “buy” rating and issued a GBX 6,900 ($90.16) target price on shares of AstraZeneca in a research report on Friday, July 26th. Barclays set a GBX 7,600 ($99.31) target price on shares of AstraZeneca and gave the company a “buy” rating in a research report on Friday, August 9th. ...